.png)
Read More
Research
Clinical research is ongoing and more than 10,000 studies have been published on light therapy or photobiomodulation for various conditions.
Research Efforts
Completed
Completed
In Progress
In Progress
Completed
Use of either transcranial or whole-body photobiomodulation treatments improves COVID-19 brain fog.
This study looked at the effects of photobiomodulation (PBM) therapy on long COVID symptoms like chronic fatigue and brain fog. It tested two devices: a helmet for the head (transcranial PBM) and a light bed for the whole body. Over four weeks, two groups of seven people each received 12 treatments. Cognitive tests and brain activity were measured before and after the therapy, showing significant improvements in both. The findings suggest that PBM intervention, whether for the brain or body, may help treat brain fog in long COVID patients.
Completed
Neuradiant 1070 & NeuroCatch® Platform Case Study Report.
This case study used a photobiomodulation (PBM) protocol with the Neuradiant 1070 device on a healthy individual, set at 70 Hz for 12 minutes at 75% intensity. Brain activity was then recorded with the NeuroCatch® Platform, which measures amplitude (brain activity strength) and latency (response speed). Higher amplitudes reflect stronger activity, while shorter latencies suggest faster processing. At baseline, the individual showed smaller amplitudes and longer latencies in their N100 (Auditory Sensation) and P300 (Basic Attention) responses, with N100 at 2.2 μV/298 ms and P300 at 3.9 μV/320 ms, indicating reduced brain activity but still within the normal range.
In Progress
tPBM with mild cognitive impairment and early-stage Alzheimer's
In this clinical trial, we will be evaluating various transcranial photobiomodulation (tPBM) protocols utilizing the Neuradiant device as an intervention for Mild Cognitive Impairment and early-stage dementia due to Alzheimer’s disease.
In Progress
Transcranial photobiomodulation therapy in patients with Alzheimer's disease
Multicenter, prospective, double-blinded, randomized clinical trial investigates the effects of transcranial Photobiomodulation (tPBM) therapy on cognitive function in patients diagnosed with mild to moderate Alzheimer's disease.
In Progress
Comparing pulsed and continuous transcranial photobiomodulation to placebo in people with chronic fatigue – a pilot double blinded randomised placebo-controlled trial
This pilot double-blinded, randomized, placebo-controlled trial compares the effects of pulsed and continuous transcranial Photobiomodulation (tPBM) to a placebo in individuals with chronic fatigue. The study aims to assess the efficacy of different tPBM protocols in managing chronic fatigue.
In Progress
Retrospective analysis of photobiomodulation with and without tDCS
Open-label trial focused on participants experiencing chronic fatigue, incorporating Photobiomodulation (PBM) and Neurofeedback (NFB) therapy. The study includes patients suffering from chronic fatigue related to long-COVID, fibromyalgia, burnout, and PTSD, aiming to explore the effectiveness of these interventions in reducing fatigue and improving overall well-being.
In Progress
An Investigation of Transcranial Magnetic Stimulation and Photobiomodulation on Major Depressive Disorder and Alzheimer’s Disease
A within-subjects study to evaluate the effects of Deep Transcranial Magnetic Stimulation (TMS) and Photobiomodulation (PBM) on behavioral, cognitive, and neurophysiological measures. The research includes two participant groups: individuals with Major Depressive Disorder and those with late-onset Alzheimer's Disease.
In Progress
EVANTHEA Memory Loss Reversal Trial
The EVANTHEA Trial is a randomized, controlled study aimed at evaluating the effectiveness of precision medicine in treating early dementia and Mild Cognitive Impairment (MCI).
In Progress
Enhancing Cognitive Performance using Transcranial Photobiomodulation
This study aims to evaluate the effects of transcranial photobiomodulation (tPBM) on cognitive performance, specifically in tasks involving vigilance and working memory. The research predicts enhanced cognitive performance and mood in the tPBM group compared to the sham group, with cumulative improvements across sessions.
Well Researched
We are developing cutting-edge devices and invest 100% profits into product development and clinical research in the effort to obtain medical approval.
Partnership formed to develop real-time, AI driven, stimulation protocols.
Neuronic, a multi-national company focused on light therapy technology, and Santa Clara University (SCU) in Silicon Valley, has announced a partnership to develop a research project to study photobiomodulation (PBM) guided by real-time brain activity, which will be led by Dr. Julia A. Scott and Dr. Sally Wood.
Light Therapy Alleviates Long COVID Brain Fog Symptoms
Dr. Robert Bowen and Dr. Praveen Arany led an open-label, proof-of-concept clinical study, entitled “Use of Either Transcranial and Whole-Body Photobiomodulation Treatments Improves COVID-19 Brain Fog“ which examined the efficacy of two photobiomodulation devices for improving Long COVID symptoms, specifically brain fog and general fatigue.
Neuronic supports all research efforts
Neuronic stands at the forefront of supporting cutting-edge research efforts, offering a comprehensive suite of services tailored to foster innovation and breakthroughs in the scientific community.
- Advising on research projects
- Donation of devices upon meeting criteria
- Discounts on devices if eligible
- Limited funding for trials
- Collaboration in general research
Supported by Research at Trusted Institutes
Shepherd University
Shepherd University is a public liberal arts college in Shepherdstown, West Virginia. It is accredited by the Higher Learning Commission. Shepherd University recently had opened it's own center of excellence for photobiomodulation equipment and research. We acknowledge Shepherd University and the West Virginia Governor Jim Justice's office for providing funding for the study on Long Covid.
West Virginia University
West Virginia University is a public land-grant research university with its main campus in Morgantown, West Virginia. WestVirginia University was a collaborator on the study titled "Use of either transcranial or whole-body photobiomodulation treatments improves COVID-19brain fog" which was published by Wiley in the Journal of Biophotonics.
Mater Research
Mater Research is a leader in medical research, translating scientific discovery into better patient care through partnerships with Mater Health, The University of Queensland, and the Translational Research Institute. In collaboration with Neuronic, they are now conducting a study on delirium patients.
Santa Clara University
Santa Clara University, founded in 1851, is California’s oldest operating higher education institution. Neuronic is sponsoring research there on designing and evaluating a closed-loop hybrid EEG and transcranial photobiomodulation system.
University at Buffalo
The State University of New York at Buffalo, commonly called the University at Buffalo and sometimes called SUNY Buffalo, is a public research university with campuses in Buffalo and Amherst, New York, United States. The University of Buffalo was a collaborator in the Long Covid study published with the Neuradiant 1070 device.
10,000+ Studies show, Light Therapy has a Positive Impact
Clinical research is ongoing and studies have been published on light therapy for various conditions and diseases.
.webp)
Collaborate with us
We welcome inquiries and look forward to exploring potential partnerships in our shared field of interest.
Neuronic is advancing research on photobiomodulation in various efforts. If you are interested in conducting research with us please get in touch!